Risk factors and comorbidities in the preclinical stages of chronic obstructive pulmonary disease

American Journal of Respiratory and Critical Care Medicine

Volumn 189, Issue 1, 2014, Pages 30-38

  Van Remoortel, Hans ^a,b   Hornikx, Miek ^a,b   Langer, Daniel ^a,b   Burtin, Chris ^a,b   Everaerts, Stephanie ^b   Verhamme, Peter ^c   Boonen, Steven ^b   Gosselink, Rik ^a,b   Decramer, Marc ^b   Troosters, Thierry ^a,b   Janssens, Wim ^b  

^a Faculty of Kinesiology and Rehabilitation Sciences   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Cardiovascular; Metabolic; Motor activity; Musculoskeletal diseases

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTERIAL WALL THICKNESS; ARTICLE; BODY MASS; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HEART DISEASE; HEART INFARCTION; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUSCULOSKELETAL DISEASE; OBESITY; OSTEOPOROSIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSICAL INACTIVITY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PULSE WAVE; RISK ASSESSMENT; RISK FACTOR; SMOKING; SPIROMETRY; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84891845870     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201307-1240OC     Document Type: Article

References (44)

1. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-365.
2. Decramer M, Rennard S, Troosters T, Mapel DW, Giardino N, Mannino D, Wouters E, Sethi S, Cooper CB. COPD as a lung disease with systemic consequences-clinical impact, mechanisms, and potential for early intervention. COPD 2008;5:235-256.
3. Fabbri LM, Luppi F, Beghé B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J 2008;31:204-212.
4. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, Zulueta J, Cabrera C, Zagaceta J, Hunninghake G, et al.; BODE Collaborative Group. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186:155-161.
5. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008;32:962-969.
6. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: Role of comorbidities. Eur Respir J 2006;28:1245-1257.
7. Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, MacNee W, Miller BE, Rennard S, Silverman EK, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010;11:122.
8. Vanfleteren LE, Spruit MA, Groenen M, Gaffron S, van Empel VP, Bruijnzeel PL, Rutten EP, Op't Roodt J, Wouters EF, Franssen FM. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187:728-735.
9. Thompson WR, Gordon NF, Pescatello LS. Preparticipation health screening and risk stratification. In: Thompson WR, Gordon NF, Pescatello, editors. ACSM's guidelines for exercise testing and prescription, 8th ed. Philadelphia: Lippincott Williams and Wilkins; 2010. pp. 18-41.
10. Fifth Joint Task Force of the European Society of Cardiology; European Association of Echocardiography; European Association of Percutaneous Cardiovascular Interventions; European Heart Rhythm Association; Heart Failure Association; European Association for Cardiovascular Prevention & Rehabilitation; European Atherosclerosis Society; International Society of Behavioural Medicine; European Stroke Organisation; European Society of Hypertension; European Association for the Study of Diabetes; European Society of General Practice/Family Medicine; International Diabetes Federation Europe; European Heart Network. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur J Prev Cardiol 2012;19: 585-667.
11. Decramer M, Janssens W. Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med 2013;1:73-83.
12. Edwards R. The problem of tobacco smoking. BMJ 2004;328: 217-219.
13. Shrikrishna D, Patel M, Tanner RJ, Seymour JM, Connolly BA, Puthucheary ZA, Walsh SL, Bloch SA, Sidhu PS, Hart N, et al. Quadriceps wasting and physical inactivity in patients with COPD. Eur Respir J 2012;40:1115-1122.
14. Watz H, Waschki B, Boehme C, Claussen M, Meyer T, Magnussen H. Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. Am J Respir Crit Care Med 2008;177:743-751.
15. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005;294:716-724.
16. Burgel PR, Paillasseur JL, Caillaud D, Tillie-Leblond I, Chanez P, Escamilla R, Court-Fortune I, Perez T, Carré P, Roche N; Initiatives BPCO Scientific Committee. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J 2010;36:531-539.
17. Van Remoortel H, Hornikx M, Langer D, Burtin C, Everaerts S, Verhamme P, Boonen S, Gosselink R, Decramer M, Troosters T, et al. Prevalence and risk factors of comorbidities in subjects with mild and moderate COPD detected by screening [abstract]. Eur Respir J 2013;42 (Suppl 57):A4852.
18. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip MS, Zheng J, et al.; ERS Global Lung Function Initiative. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J 2012;40:1324-1343.
19. Rosenberg E. The 1995 update of recommendations for a standard technique for measuring the single-breath carbon monoxide diffusing capacity (transfer factor). Am J Respir Crit Care Med 1996; 154:265-266.
20. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999;54:581-586.
21. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, et al.; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
22. Rabinovich RA, Louvaris Z, Raste Y, Langer D, Remoortel HV, Giavedoni S, Burtin C, Regueiro EM, Vogiatzis I, Hopkinson NS, et al. Validity of physical activity monitors during daily life in patients with COPD. Eur Respir J [online ahead of print] 14 Jan 2013; DOI: 10.1183/09031936.00134312.
23. Van Remoortel H, Raste Y, Louvaris Z, Giavedoni S, Burtin C, Langer D, Wilson F, Rabinovich R, Vogiatzis I, Hopkinson NS, et al.; PROactive consortium. Validity of six activity monitors in chronic obstructive pulmonary disease: a comparison with indirect calorimetry. PLoS ONE 2012;7:e39198.
24. Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, Macera CA, Heath GW, Thompson PD, Bauman A. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc 2007;39:1423-1434.
25. Tudor-Locke C, Schuna JM Jr. Steps to preventing type 2 diabetes: exercise, walk more, or sit less? Front Endocrinol (Lausanne) 2012;3: 142.
26. Nelson ME, Rejeski WJ, Blair SN, Duncan PW, Judge JO, King AC, Macera CA, Castaneda-Sceppa C. Physical activity and public health in older adults: recommendation from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc 2007;39:1435-1445.
27. Energy and protein requirements. Report of a joint FAO/WHO/UNU Expert Consultation. World Health Organ Tech Rep Ser 1985;724: 1-206.
28. Scheers T, Philippaerts R, Lefevre J. Variability in physical activity patterns as measured by the Sense Wear Armband: how many days are needed? Eur J Appl Physiol 2012;112:1653-1662.
29. Razali NM, Wah YB. Power comparisons of Shapiro-Wilk, Kolmogorov-Smirnov, Lilliefors and Anderson-Darling tests. J Stat Model Anal 2011;2:21-33.
30. Siebeling L, Puhan MA, Muggensturm P, Zoller M, Ter Riet G. Characteristics of Dutch and Swiss primary care COPD patients-baseline data of the ICE COLD ERIC study. Clin Epidemiol 2011;3: 273-283.
31. Rutten FH, Cramer MJ, Zuithoff NP, Lammers JW, Verweij W, Grobbee DE, Hoes AW. Comparison of B-type natriuretic peptide assays for identifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease. Eur J Heart Fail 2007;9:651-659.
32. Huelsmann M, Neuhold S, Resl M, Strunk G, Brath H, Francesconi C, Adlbrecht C, Prager R, Luger A, Pacher R, et al. PONTIAC (NTpro BNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. J Am Coll Cardiol 2013;62:1365-1372.
33. De Sutter J, De Bacquer D, Cuypers S, Delanghe J, De Buyzere M, Kornitzer M, De Backer G. Plasma N-terminal pro-brain natriuretic peptide concentration predicts coronary events in men at work: a report from the BELSTRESS study. Eur Heart J 2005;26: 2644-2649.
34. Linssen GC, Bakker SJ, Voors AA, Gansevoort RT, Hillege HL, de Jong PE, van Veldhuisen DJ, Gans RO, de Zeeuw D. N-terminal pro-Btype natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. Eur Heart J 2010; 31:120-127.
35. Sabit R, Bolton CE, Edwards PH, Pettit RJ, Evans WD, McEniery CM, Wilkinson IB, Cockcroft JR, Shale DJ. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:1259-1265.
36. Soriano JB, Zielinski J, Price D. Screening for and early detection of chronic obstructive pulmonary disease. Lancet 2009;374:721-732.
37. Glantz S, Gonzalez M. Effective tobacco control is key to rapid progress in reduction of non-communicable diseases. Lancet 2012; 379:1269-1271.
38. Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT; Lancet Physical Activity Series Working Group. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet 2012;380: 219-229.
39. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012;380:37-43.
40. de Blok BM, de Greef MH, ten Hacken NH, Sprenger SR, Postema K, Wempe JB. The effects of a lifestyle physical activity counseling program with feedback of a pedometer during pulmonary rehabilitation in patients with COPD: a pilot study. Patient Educ Couns 2006;61:48-55.
41. Hospes G, Bossenbroek L, Ten Hacken NH, van Hengel P, de Greef MH. Enhancement of daily physical activity increases physical fitness of outclinic COPD patients: results of an exercise counseling program. Patient Educ Couns 2009;75:274-278.
42. Agustí A, Faner R. Systemic inflammation and comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2012;9:43-46.
43. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009;33:1165-1185.
44. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet 2007;370:797-799.